DocGo stock touches 52-week low at $2.63 amid market shifts

In a challenging market environment, DocGo Inc. (DCGO) stock has recorded a new 52-week low, dipping to $2.63. According to InvestingPro data, the company maintains strong financial health with a current ratio of 2.5 and more cash than debt on its balance sheet. The mobile health services provider has faced significant headwinds over the past year, reflected in the stock’s performance with a 1-year change showing a substantial decline of 34.78%. Investors are closely monitoring the company’s strategic moves to navigate through the current market conditions, which have been unforgiving to many in the healthcare sector. Technical indicators from InvestingPro suggest the stock is currently in oversold territory, and analysis indicates the company is trading below its Fair Value. DocGo’s ability to adapt and innovate will be critical as they attempt to recover from this low point and regain investor confidence. For deeper insights and additional ProTips about DCGO, explore the comprehensive Pro Research Report available on InvestingPro.

In other recent news, DocGo Inc. reported its fourth-quarter 2024 earnings, revealing a decline in revenue to $120.8 million, which was below the expected $124.26 million. The company experienced a net loss of $7.6 million for the quarter, contrasting with a net income of $8 million in the same period last year. Full-year revenue for 2024 was slightly down by 1% from the previous year, although net income increased by 34% to $13.4 million. Deutsche Bank (ETR:DBKGn) downgraded DocGo’s stock from ’Buy’ to ’Hold,’ citing uncertainties related to the company’s transition to a new business model and revised its 2025 EBITDA estimate to $21 million. Cantor Fitzgerald also revised its price target for DocGo, lowering it to $4.00 from $5.00, while maintaining an Overweight rating due to concerns over EBITDA margins and revenue shortfalls. Despite these challenges, Cantor Fitzgerald expressed confidence in the management’s strategic direction. DocGo is focusing on growth in its Care Gap Closure Program and has set a 2025 revenue guidance between $410 million and $450 million, with a focus on expanding its transportation segment.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.